Bloomberg News

Novo's Victoza Leads to Greater Weight Loss Than Byetta

June 10, 2012

Novo Nordisk A/S (NOVOB) said patients taking its Victoza diabetes drug had greater weight loss than those using Amylin Pharmaceuticals Inc. (AMLN:US)’s Byetta or a class of drug known as DPP-4 inhibitors.

Novo is presenting the data at the American Diabetes Association’s annual meeting in Philadelphia today. The company, which is studying Victoza as a possible obesity treatment, commented in an e-mailed statement.

Patients taking Victoza lost 3.9 kilograms (8.6 pounds) on average, compared with 0.8 kilogram for those on DPP-4 drugs and 2.9 kilograms for those taking Byetta, Novo Nordisk said.

To contact the reporter on this story: Phil Serafino in Paris at pserafino@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net


Hollywood Goes YouTube
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

 
blog comments powered by Disqus